Your browser is no longer supported. Please, upgrade your browser.
NVO [NYSE]
Novo Nordisk A/S
Index- P/E25.16 EPS (ttm)2.90 Insider Own26.40% Shs Outstand2.33B Perf Week2.53%
Market Cap130.94B Forward P/E23.29 EPS next Y3.13 Insider Trans0.00% Shs Float1.13B Perf Month1.29%
Income6.80B PEG17.09 EPS next Q0.64 Inst Own8.00% Short Float0.36% Perf Quarter2.79%
Sales20.81B P/S6.29 EPS this Y2.80% Inst Trans0.01% Short Ratio3.54 Perf Half Y9.65%
Book/sh4.18 P/B17.42 EPS next Y6.94% ROA31.50% Target Price74.19 Perf Year18.25%
Cash/sh2.32 P/C31.41 EPS next 5Y1.47% ROE71.70% 52W Range49.24 - 73.92 Perf YTD4.27%
Dividend1.04 P/FCF26.15 EPS past 5Y10.20% ROI69.10% 52W High-1.47% Beta0.46
Dividend %1.43% Quick Ratio0.80 Sales past 5Y6.60% Gross Margin83.70% 52W Low47.91% ATR1.29
Employees44326 Current Ratio1.00 Sales Q/Q2.10% Oper. Margin43.10% RSI (14)59.68 Volatility1.27% 1.33%
OptionableYes Debt/Eq0.07 EPS Q/Q2.70% Profit Margin32.60% Rel Volume0.70 Prev Close72.52
ShortableYes LT Debt/Eq0.04 Earnings- Payout281.20% Avg Volume1.15M Price72.83
Recom3.00 SMA203.07% SMA505.05% SMA2008.75% Volume797,381 Change0.43%
Jan-20-21Downgrade Credit Suisse Outperform → Neutral
Jan-15-21Initiated Deutsche Bank Buy
Sep-29-20Initiated Berenberg Hold
Jul-06-20Downgrade BofA Securities Buy → Neutral
May-11-20Downgrade UBS Buy → Neutral
May-04-20Initiated Cowen Market Perform $72
Mar-16-20Upgrade BofA/Merrill Neutral → Buy
Jan-03-20Downgrade Guggenheim Buy → Neutral
Nov-18-19Upgrade Barclays Equal Weight → Overweight
Sep-17-19Upgrade Citigroup Neutral → Buy
Aug-30-19Downgrade Jefferies Hold → Underperform
Jun-20-19Downgrade Deutsche Bank Buy → Hold
Jun-11-19Upgrade Barclays Underweight → Equal Weight
Apr-29-19Upgrade Credit Suisse Neutral → Outperform
Jan-29-19Initiated Exane BNP Paribas Outperform
Dec-11-18Resumed Jefferies Hold
Oct-09-18Initiated Guggenheim Buy
Dec-29-17Upgrade JP Morgan Underweight → Neutral
Dec-06-17Upgrade BofA/Merrill Neutral → Buy
Dec-01-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-21-21 12:16PM  
Jan-20-21 10:08AM  
Jan-18-21 04:25AM  
Jan-11-21 07:14AM  
Jan-04-21 09:14AM  
Dec-30-20 11:25AM  
Dec-29-20 06:12AM  
Dec-22-20 05:32AM  
Dec-21-20 10:13AM  
Dec-19-20 10:10PM  
Dec-18-20 02:10AM  
Dec-16-20 08:08AM  
Dec-14-20 11:08AM  
Dec-09-20 12:15PM  
Dec-08-20 04:05PM  
01:22PM  
06:30AM  
Dec-07-20 09:27AM  
09:27AM  
09:11AM  
09:04AM  
Dec-04-20 09:33PM  
07:29AM  
Nov-30-20 08:48AM  
Nov-25-20 09:35AM  
Nov-23-20 12:56PM  
08:36AM  
Nov-20-20 08:42AM  
Nov-18-20 11:24AM  
01:29AM  
Nov-17-20 09:24AM  
Nov-16-20 01:54PM  
01:31PM  
09:49AM  
Nov-12-20 12:33PM  
09:07AM  
Nov-11-20 12:56PM  
Nov-09-20 06:18PM  
01:46PM  
06:50AM  
06:20AM  
Nov-06-20 04:38PM  
09:26AM  
09:09AM  
02:30AM  
Nov-05-20 09:00AM  
03:56AM  
Nov-03-20 02:59PM  
02:55PM  
02:49PM  
Oct-30-20 07:01PM  
10:54AM  
02:30AM  
Oct-29-20 06:01AM  
Oct-26-20 08:47AM  
Oct-19-20 06:50PM  
11:40AM  
07:24AM  
Oct-13-20 03:31PM  
Oct-12-20 04:14AM  
Oct-11-20 01:52PM  
Oct-09-20 01:41PM  
12:30PM  
03:04AM  
Oct-08-20 12:40PM  
Oct-05-20 08:35AM  
Sep-29-20 06:47PM  
08:44AM  
Sep-28-20 08:20AM  
03:02AM  
Sep-24-20 04:30AM  
Sep-22-20 08:46AM  
Sep-21-20 02:03PM  
10:13AM  
Sep-18-20 03:14PM  
11:40AM  
Sep-16-20 10:19PM  
Sep-14-20 04:59AM  
Sep-07-20 08:02AM  
Aug-31-20 09:03AM  
Aug-26-20 03:38PM  
Aug-24-20 09:24AM  
Aug-17-20 08:59AM  
Aug-14-20 09:18AM  
Aug-13-20 05:11AM  
Aug-11-20 10:42AM  
Aug-07-20 12:24PM  
11:30AM  
Aug-06-20 11:34AM  
01:53AM  
01:43AM  
01:30AM  
Aug-05-20 07:05AM  
Jul-30-20 07:32PM  
Jul-28-20 05:35PM  
Jul-20-20 05:49AM  
Jul-17-20 07:13PM  
Jul-16-20 09:28AM  
Jul-13-20 10:27AM  
06:02AM  
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharmaceuticals. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. Novo Nordisk A/S also has collaboration agreements with Lund University to develop stem cell-derived treatment for Parkinson's diseases; Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia; Medtronic plc to develop integrated digital solutions for people with diabetes; and bluebird bio, Inc. to develop in vivo genome editing treatments for genetic diseases, as well as research collaboration and license agreement with Procyon Technologies LLC to develop an implantable cell encapsulation device to be used in a novel therapy for Type 1 diabetes. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.